Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study

被引:9
|
作者
Mehta, Rupal [1 ,2 ]
Ying, Gui Shuang [3 ]
Houston, Samuel [4 ]
Isakova, Tamara [1 ,2 ]
Nessel, Lisa [3 ]
Ojo, Akinlolu [5 ]
Go, Alan [6 ]
Lash, Jim [7 ]
Kusek, John [8 ]
Grunwald, Juan [3 ]
Wolf, Myles [1 ,2 ]
Invest, C. R. I. C. Study
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Nephrol & Hypertens, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Translat Metab & Hlth, Chicago, IL 60611 USA
[3] Univ Penn, Philadelphia, PA 19104 USA
[4] Wills Eye Hosp & Res Inst, Philadelphia, PA USA
[5] Univ Michigan, Ann Arbor, MI 48109 USA
[6] Kaiser Permanente, Oakland, CA USA
[7] Univ Illinois, Chicago, IL USA
[8] NIDDK, Bethesda, MD 20892 USA
关键词
CKD; FGF-23; phosphate; retinopathy; vascular disease; RETINAL MICROVASCULAR ABNORMALITIES; CARDIOVASCULAR-DISEASE; SERUM PHOSPHORUS; ATHEROSCLEROSIS RISK; ARTERY-DISEASE; HEART-FAILURE; ALL-CAUSE; MORTALITY; ASSOCIATIONS; CALCIUM;
D O I
10.1093/ndt/gfv123
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Elevated circulating concentrations of phosphate and fibroblast growth factor 23 (FGF23) contribute to the pathogenesis of cardiovascular disease in chronic kidney disease (CKD). Retinopathy is a common manifestation of microvascular disease in CKD, but its associations with phosphate and FGF23 have not been studied. We tested the hypothesis that higher serum phosphate is associated with more severe retinopathy in individuals with CKD, independent of FGF23 and known risk factors for retinopathy. We tested the associations of serum phosphate and plasma FGF23 with retinopathy in a cross-sectional analysis of 1800 participants in the Chronic Renal Insufficiency Cohort Study who underwent fundus photography. Retinopathy severity was graded according to the Early Treatment of Diabetic Retinopathy Severity score, and retinal venous and arterial diameters were measured. Mean estimated glomerular filtration rate (eGFR) was 46.5 +/- 15.4 mL/min/1.73 m(2), mean serum phosphate was 3.7 +/- 0.6 mg/dl and median plasma C-terminal FGF23 was 133 RU/mL (interquartile range 87.2, 217.8 RU/mL). In multivariable ordinal logistic regression models, higher serum phosphate was associated with greater retinopathy severity independent of hypertension, diabetes, CKD severity and FGF23 [adjusted odds ratio of being in one higher category of retinopathy severity: 1.19 per 1 standard deviation increase; 95% confidence interval (CI) 1.05, 1.36; P = 0.007]. Presence of diabetes or hypertension did not modify the results. Higher serum phosphate was also independently associated with greater retinal venous diameter (multivariable-adjusted 1.70 A mu m increase per 1 standard deviation increase in phosphate; 95% CI 0.46, 2.93; P = 0.007). FGF23 levels were not independently associated with retinopathy severity or retinal venous diameter, and neither FGF23 nor phosphate was associated with retinal arterial diameter. Among individuals with moderate-to-severe CKD, higher serum phosphate but not FGF23 was independently associated with more severe retinopathy and microvascular retinal venous dilatation.
引用
收藏
页码:1534 / 1541
页数:8
相关论文
共 50 条
  • [21] Fibroblast Growth Factor 23/Klotho Axis in Chronic Kidney Disease
    Nitta, Kosaku
    Nagano, Nobuo
    Tsuchiya, Ken
    NEPHRON CLINICAL PRACTICE, 2014, 128 (1-2): : 1 - 10
  • [22] A prospective study of fibroblast growth factor-23 in children with chronic kidney disease
    Magnusson, Per
    Hansson, Sverker
    Swolin-Eide, Diana
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2010, 70 (01): : 15 - 20
  • [23] STUDY OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE STAGE II TO IV
    Gohel, Kalpesh
    Saurin, Dalal
    Hegde, Umapati
    Gang, Sishir
    Rajapurkar, Mohan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 354 - 354
  • [24] Fibroblast growth factor 23 and cardiovascular disease in patients with chronic kidney disease
    Nitta K.
    Renal Replacement Therapy, 4 (1)
  • [25] Fibroblast growth factor 23 (FGF-23) in chronic kidney disease and post renal transplantation.
    Pande, S
    Ritter, CS
    Schiavi, SC
    Brown, AJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 207A - 207A
  • [26] Habitual sleep and kidney function in chronic kidney disease: the Chronic Renal Insufficiency Cohort study
    Knutson, Kristen L.
    Lash, James
    Ricardo, Ana C.
    Herdegen, James
    Thornton, J. D.
    Rahman, Mahboob
    Turek, Nicolas
    Cohan, Janet
    Appel, Lawrence J.
    Bazzano, Lydia A.
    Tamura, Manjula K.
    Steigerwalt, Susan P.
    Weir, Matthew R.
    Van Cauter, Eve
    JOURNAL OF SLEEP RESEARCH, 2018, 27 (02) : 281 - 289
  • [27] Fibroblast growth factor 23 (FGF 23) and phosphocakic metabolism in chronic kidney disease
    Torguet-Escuder, Pere
    Guasch-Aragay, Bernat
    Calabia-Martinez, Jordi
    Martin-Alemany, Nadia
    Garcia-Mendez, Isabel
    Mate-Benito, Gerard
    Clapes-Sanchez, Esther
    Sabater-Masdeu, Monica
    Fernandez-Real, Jose M.
    Valles-Prats, Marti
    NEFROLOGIA, 2012, 32 (05): : 647 - 654
  • [28] Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort
    Marc G Vervloet
    Arjan D van Zuilen
    Annemieke C Heijboer
    Piet M ter Wee
    Michiel L Bots
    Peter J Blankestijn
    Jack FM Wetzels
    BMC Nephrology, 13
  • [29] Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort
    Vervloet, Marc G.
    van Zuilen, Arjan D.
    Heijboer, Annemieke C.
    ter Wee, Piet M.
    Bots, Michiel L.
    Blankestijn, Peter J.
    Wetzels, Jack F. M.
    BMC NEPHROLOGY, 2012, 13
  • [30] Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model
    Sugiura, Hidekazu
    Matsushita, Al
    Futaya, Mayuko
    Teraoka, Atsuko
    Akiyama, Ken-ichi
    Usui, Noriyoshi
    Nagano, Nobuo
    Nitta, Kosaku
    Tsuchiya, Ken
    PLOS ONE, 2018, 13 (03):